Literature DB >> 10869769

Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2. Enhancement of protection by the co-delivery of the GM-CSF gene.

J Fló1, A Beatriz Perez, S Tisminetzky, F Baralle.   

Abstract

Immunization with naked DNA has been analyzed in two critical variables: the site of injection and the cellular compartment to which the coded protein is directed. The gene for the full length of the glycoprotein D (gD) of HSV-2 under the control of the citomegalovirus (CMV) promoter was injected via the intradermal (i.d.) or the intramuscular (i.m.) routes in mice. Immunization in the quadricep muscle was superior to the intradermal immunization in the footpads. A stronger activation of IFN-gamma-secreting cells in the spleen and draining lymph nodes (DLN) was induced, resulting in a more efficient protection against an intravaginal challenge. In order to analyze the effect of the cellular localizations of the coded protein, the DNA for the truncated form of the gD (DeltagD) was injected via the i.m. route. Immunization with a vector encoding for DeltagD resulted in higher antibody levels in serum and vaginal washes than immunization with the gene for the full length gD. However, immunization with the DeltagD DNA elicited a much weaker cell-mediated immune response and was inferior to gD DNA in providing protection against a lethal intravaginal challenge with HSV. Co-injection of an expression cassette for the granulocyte-macrophage colony-stimulating factor (GM-CSF) increased both the humoral and cell-mediated immune response with both gD and DeltagD. A strong activation of IL-4-secreting cells was observed in the spleen and DLN together with an increase in the number of IFN-gamma-secreting cells. In addition, a reduction in the vaginal virus titers after an intravaginal challenge was observed in mice co-injected with the GM-CSF gene as compared to those immunized with pCDNAgD only.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869769     DOI: 10.1016/s0264-410x(00)00132-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Effect of granulocyte-macrophage colony-stimulating factor on post-weaning multisystemic wasting syndrome in porcine circovirus type-2-transfected piglets.

Authors:  Christophe Loizel; Philippe Blanchard; Béatrice Grasland; Daniel Dory; Aurélie Oger; Anne-Cécile Nignol; Roland Cariolet; André Jestin
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

Review 2.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 3.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

4.  Development of DNA vaccines against hemolytic-uremic syndrome in a murine model.

Authors:  Alejandra V E Capozzo; Virginia Pistone Creydt; Graciela Dran; Gabriela Fernández; Sonia Gómez; Leticia V Bentancor; Carolina Rubel; Cristina Ibarra; Martín Isturiz; Marina S Palermo
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

5.  Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates.

Authors:  Joseph W Golden; Matthew Josleyn; Eric M Mucker; Chien-Fu Hung; Peter T Loudon; T C Wu; Jay W Hooper
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

6.  Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.

Authors:  V Durmanová; M Sapák; J Kosovský; I Rezuchová; M Kúdelová; M Buc; J Rajcáni
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.